D
Dale G. Renlund
Researcher at University of Utah
Publications - 200
Citations - 11055
Dale G. Renlund is an academic researcher from University of Utah. The author has contributed to research in topics: Transplantation & Heart transplantation. The author has an hindex of 56, co-authored 200 publications receiving 10629 citations. Previous affiliations of Dale G. Renlund include Primary Children's Hospital & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Which White Blood Cell Subtypes Predict Increased Cardiovascular Risk
Benjamin D. Horne,Jeffrey L. Anderson,Jeffrey L. Anderson,Jerry M. John,Jerry M. John,Aaron N. Weaver,Aaron N. Weaver,Tami L Bair,Kurt R. Jensen,Dale G. Renlund,Dale G. Renlund,Joseph B. Muhlestein,Joseph B. Muhlestein +12 more
TL;DR: Total WBC count is confirmed to be an independent predictor of death/MI in patients with or at high risk for CAD, but greater predictive ability is provided by high N (Q4 >6.6 x 10(3)/microl) or low L counts.
Journal ArticleDOI
A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.
Jon A. Kobashigawa,Leslie W. Miller,Dale G. Renlund,Robert M. Mentzer,Edwin L. Alderman,Robert C. Bourge,Maria Rosa Costanzo,Howard J. Eisen,Georges Dureau,R. Ratkovec,Manfred Hummel,David Ipe,Jay A. Johnson,Anne Keogh,Richard D. Mamelok,Donna Mancini,Frank W. Smart,Hannah A. Valantine +17 more
TL;DR: Substitution of MMF for azathioprine may reduce mortality and rejection in the first year after cardiac transplantation.
Journal ArticleDOI
Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study
Olsen Sl,Edward M. Gilbert,Dale G. Renlund,David O. Taylor,Frank D. Yanowitz,Michael R. Bristow +5 more
TL;DR: Long-term carvedilol therapy improves rest cardiac function and lessens symptoms in patients with heart failure and resulted in a significant reduction in heart rate and mean pulmonary artery and pulmonary capillary wedge pressures and a significant increase in stroke volume and left ventricular stroke work.
Journal ArticleDOI
Risk Factors Predictive of Right Ventricular Failure After Left Ventricular Assist Device Implantation
Stavros G. Drakos,Stavros G. Drakos,Stavros G. Drakos,Lindsay Janicki,Lindsay Janicki,Benjamin D. Horne,Abdallah G. Kfoury,Abdallah G. Kfoury,Bruce B. Reid,Bruce B. Reid,Stephen E. Clayson,Kenneth Horton,Francois Haddad,Dean Y. Li,Dale G. Renlund,Dale G. Renlund,Patrick W. Fisher +16 more
TL;DR: In this article, the authors developed a risk score for right ventricular failure after left ventricular assist device (LVAD) implantation, which was defined by the need for inhaled nitric oxide for ≥48 hours or intravenous inotropes for >14 days.
Journal ArticleDOI
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
Thomas C. Merigan,Dale G. Renlund,Susan Keay,Michael R. Bristow,Vaughn A. Starnes,John B. O'Connell,Silvia Resta,Diane Dunn,P. Gamberg,Ranae M. Ratkovec,Wayne E. Richenbacher,Roger C. Millar,Charles DuMond,Bernadette DeAmond,Veronica Sullivan,Tricia Cheney,William Buhles,Edward B. Stinson +17 more
TL;DR: The prophylactic administration of ganciclovir after heart transplantation is safe, and inCMV-seropositive patients it reduces the incidence of CMV-induced illness.